Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retatrutide - Eli Lilly and Company

Drug Profile

Retatrutide - Eli Lilly and Company

Alternative Names: GGG Tri-agonist - Eli Lilly and Company; GLP-1/GIP/glucagon tri-agonist - Eli Lilly and Company; LY-3437943

Latest Information Update: 14 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antihyperglycaemics; Cardiovascular therapies; Obesity therapies; Peptides
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cardiovascular disorders; Obesity; Osteoarthritis; Sleep apnoea syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 30 Apr 2024 Phase-III clinical trials in Obesity in Slovakia, Romania, Israel, Germany, France, Denmark, Czech Republic, Brazil, Austria (SC) (NCT06383390)
  • 30 Apr 2024 Eli Lilly and Company initiates a phase III TRIUMPH-OUTCOMES trial for Obesity in USA, Argentina, Australia, Hungary, Puerto Rico, Canada, India, Spain and United Kingdom (SC) (NCT06383390)
  • 25 Apr 2024 Eli Lilly and Company plans to initiate a phase III (TRIUMPH-OUTCOMES) trial for Obesity in the US, Argentina, Australia, Austria, Brazil, Canada, Czechia, Denmark, France, Germany, Hungary, India, Israel, Mexico, Netherland, Poland Puerto Rico, Slovakia, Spain, Turkey and United Kingdom (SC) (NCT06383390)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top